Ionis Pharmaceuticals, Inc. (IONS) Stock
Key stats
- Market cap
- $4.72B
- Price / Earnings ratio
- -8.6x
- EPS (TTM)
- -$3.34
- Volume
- Loading
- 52-week high
- $86.74
- 52-week low
- $27.75
Source: third-party data provider, as of November 13, 2026
Compare with IONS
Recent news
Ionis to hold third quarter 2026 financial results webcast
Ionis to hold third quarter 2026 financial results webcast
IONS
Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline
Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline
IONS
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
IONS
Ionis ranked #1 on Science's Top Employers list
Ionis ranked #1 on Science's Top Employers list
IONSNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 18.04
- MACD 12/26/9
- -3.80
- EMA 9 of MACD
- -2.39
- MACD histogram
- -1.41
- SMA 50
- $44.92
- Price below SMA 50
- EMA 50
- $44.82
- Price below EMA 50
- SMA 200
- $65.04
- Price below SMA 200
- EMA 200
- $61.98
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 14 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.70 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Ionis to hold third quarter 2026 financial results webcast
Ionis to hold third quarter 2026 financial results webcast
IONSEarnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline
Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline
IONSIonis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
IONSIonis ranked #1 on Science's Top Employers list
Ionis ranked #1 on Science's Top Employers list
IONS
Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy Treatment
Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy Treatment
IONS
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
IONS
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)
IONS
Alnylam vs. Ionis: Here's the Better Bad-News Buy
Alnylam vs. Ionis: Here's the Better Bad-News Buy
IONS
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
IONS
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
IONSNews tone: automated (AI) classification of the article's content, not a price prediction.
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Brett P. Monia Ph.D. | Founder, CEO & Director | 1961 |
| Ms. Elizabeth L. Hougen M.A., M.B.A., M.S. | Executive VP of Finance & CFO | 1962 |
| Mr. Patrick R. O'Neil Esq. | Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary | 1974 |
| Dr. Eric E. Swayze Ph.D. | Executive Vice President & Head of Research | 1966 |
| Mr. Brian Birchler | Executive Vice President of Corporate & Development Operations | 1966 |
| Dr. Richard S. Geary Ph.D. | Strategic Consultant | 1958 |
| Dr. Eugene Schneider M.D. | Executive VP, Chief Clinical Development & Operations Officer | 1973 |
| Mr. Darren Gonzales | Chief Accounting Officer & Senior VP | — |
| Dr. C. Frank Bennett BSc, Ph.D. | Executive VP & Chief Scientific Officer | 1957 |
| Mr. D. Wade Walke Ph.D. | Senior Vice President of Investor Relations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 18.04
- MACD 12/26/9
- -3.80
- EMA 9 of MACD
- -2.39
- MACD histogram
- -1.41
- SMA 50
- $44.92
- Price below SMA 50
- EMA 50
- $44.82
- Price below EMA 50
- SMA 200
- $65.04
- Price below SMA 200
- EMA 200
- $61.98
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
14 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $41.00
- Average
- $69.79
- High
- $88.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -19.2 | +18.8 | ||||||||||
| 2022 | -2.5 | +5.9 | +8.7 | -5.5 | -4.8 | +3.1 | -1.3 | +13.4 | +1.8 | -1.8 | -9.0 | -6.0 |
| 2023 | +6.1 | -10.3 | -0.6 | +0.1 | +14.6 | -4.4 | +0.9 | -2.3 | +12.0 | +1.9 | +9.3 | -2.0 |
| 2024 | -2.8 | -11.3 | -4.6 | -6.1 | -12.6 | +22.9 | +5.0 | -7.1 | -15.3 | -1.7 | -7.8 | -3.2 |
| 2025 | -8.0 | +3.3 | -7.5 | +12.7 | +5.7 | +15.8 | +7.6 | -0.9 | +13.8 | +12.9 | +12.3 | -3.5 |
| 2026 | +3.8 | -2.3 | -8.4 | -0.5 | +1.6 | +5.2 | -34.6 | +10.8 | -25.4 | -1.1 | -31.3 |
